Topiramate, carbamazepine, and valproate monotherapy: double-blind comparison in children with newly diagnosed epilepsy.
Author(s): Wheless JW, Neto W, Wang S, EPMN-105 Study Group
Affiliation(s): Department of Neurology, University of Texas Health Science Center at Houston, Houston, TX, USA. James.W.Wheless@uth.tmc.edu
Publication date & source: 2004-02, J Child Neurol., 19(2):135-41.
Publication type: Clinical Trial; Randomized Controlled Trial
In a novel double-blind trial, topiramate was compared with the investigator's choice of carbamazepine or valproate as first-line therapy in patients as young as 6 years of age with newly diagnosed epilepsy. Among 613 patients enrolled in the trial, 119 (19%) were children or adolescents (6-16 years of age). No differences between fixed doses of topiramate (100 and 200 mg/day) and carbamazepine (600 mg/day) or valproate (1250 mg/day) were observed in efficacy measures: time to exit, time to first seizure, and the proportion of patients who were seizure free during the last 6 months of treatment. Topiramate 100 mg/day (2.0 mg/kg/day in this study population) was associated with the fewest discontinuations owing to side effects. Based on efficacy and tolerability, the recommended target dose for topiramate as first-line therapy in children and adolescents is 100 mg/day.
|